文献类型：期刊文献

英文题名：Research progress of Astragalus membranaceus in treating peritoneal metastatic cancer

作者：Li, Zhiyuan[2];Qi, Jinfeng[2];Guo, Tiankang[1];Li, Junliang[1,2,3]

第一作者：Li, Zhiyuan

通信作者：Li, JL[1];Li, JL[2];Li, JL[3]

机构：[1]Gansu Prov Hosp, Dept Gen Surg, Lanzhou 730030, Peoples R China;[2]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou 730030, Peoples R China;[3]Lanzhou Univ, Sch Clin Med 1, Lanzhou 730030, Peoples R China

第一机构：Gansu Prov Hosp, Dept Gen Surg, Lanzhou 730030, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Gen Surg, Lanzhou 730030, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou 730030, Peoples R China;[3]corresponding author), Lanzhou Univ, Sch Clin Med 1, Lanzhou 730030, Peoples R China.|[10735]甘肃中医药大学;

年份：2023

卷号：305

外文期刊名：JOURNAL OF ETHNOPHARMACOLOGY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000917924300001)】；

基金：This work was supported by the Natural Science Foundation of Gansu Province [grant number 20JR10RA372]; Health Industry Research Project of Gansu Province [grant number GSWSKY-2019-03]; Open Fund Project of Gansu Key Laboratory of Molecular Diagnosis and Precision Therapy of Surgical Oncology [grant number 2020GSZDSYS02]; Scientific Research and Innovation Fund of Gansu University of Chinese Medicine [grant number 2020KCYB-7]; Reform and practical exploration of the talent training model of "university-hospital co-construction" of education department of Gansu Province [grant number (2021) 5-6]; Longyuan Youth Innovation and Entrepreneurship Talent Project [grant number 111266548053]; Teaching Research and Reform Project of Gansu University of Chinese Medicine [grant number ZHXM-202207]; Lanzhou Science and Technology Bureau particular project [grant number 2020-XG-3]; and The 14th Five -Year Plan of Education Science of Gansu Province [grant number GS [2021]GHB1859].

语种：英文

外文关键词：Peritoneal metastatic cancer; Astragalus membranaceus; Tumor microenvironment; Peritoneal mesothelial cells; Tumor-associated macrophages

摘要：Ethnopharmacological relevance: Peritoneal metastasis is a manifestation of advanced cancer often associated with a poor prognosis and poor response to treatment. Astragalus membranaceus (Fisch.) Bunge is a commonly used medicinal material in traditional Chinese medicine with various biological activities. In patients with cancer, Astragalus membranaceus has demonstrated anti-tumor effects, immune regulation, postoperative recurrence and metastasis prevention, and survival prolongation. Aim of the study: Peritoneal metastasis results from tumor cell and peritoneal microenvironment co-evolution. We aimed to introduce and discuss the specific mechanism of action of Astragalus membranaceus in peritoneal metastasis treatment to provide a new perspective for treatment and further research.Materials and methods: We consulted reports on the anti-peritoneal metastases effects of Astragalus membranaceus from PubMed, Web of Science, China National Knowledge Infrastructure, and Wanfang databases, as well as Google Scholar. Meanwhile, we also obtained data from published medical works and doctoral and master's theses. Then, we focused on the research progress of Astragalus membranaceus in peritoneal metastatic cancer treatment. Plant names are provided in accordance with "The Plant List" (www.theplantlist.org).Results: To date, more than 200 compounds have been isolated from Astragalus membranaceus. Among them, Astragalus polysaccharides, saponins, and flavonoids are the main bioactive components, and their effects on cancer have been extensively studied. In this review, we systematically summarize the effects of Astragalus membranaceus on the peritoneal metastasis microenvironment and related mechanisms, including maintaining the integrity of peritoneal mesothelial cells, restoring the peritoneal immune microenvironment, and inhibiting the formation of tumor blood vessels, matrix metalloproteinase, and dense tumor spheroids. Conclusions: Our analysis demonstrates that Astragalus membranaceus could be a potential therapeutic for preventing the occurrence of peritoneal metastasis. However, it might be too early to recommend its use owing to the paucity of reliable in vivo experiment, clinical data, and evidence of clinical efficacy. In addition, previous studies of Astragalus membranaceus report inconsistent and contradictory findings. Therefore, detailed in vitro, in vivo, and clinical studies on the mechanism of Astragalus membranaceus in peritoneal metastatic cancer treatment are warranted.